Drug Trial Radar · NCT04121455
Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients
Last checked: Nov 19, 2026Latest source record: Jun 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
117
Planned (sponsor's estimate)
Start
Sep 12, 2019
Primary completion
Dec 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- TME Pharma AGIndustry
- Sponsor type
- Industry
- First posted
- Oct 10, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to obtain first, exploratory information on the safety and efficacy of (i) olaptesed pegol in combination with radiation therapy in patients with newly diagnosed glioblastoma of unmethylated MGMT promoter status either not amenable to resection (biopsy only) or after incomplete tumor resection, and (ii) olaptesed pegol in combination with radiation therapy and bevacizumab in patients with newly diagnosed glioblastoma of unmethylated MGMT promoter status either not amenable to resection (biopsy only) or after incomplete or complete tumor resection. Further arms are included (i) to establish safety for the combination of olaptesed pegol at three different doses in addition to radiotherapy and bevacizumab, (ii) to explore the benefit of combining olaptesed pegol at different dose levels with bevacizumab in order to define the doses to move forward into a subsequent randomized dose-finding study, (iii) to explore the contribution of the therapy components olaptesed pegol and bevacizumab to patient benefit and (iv) to put the clinical outcome of these treatment regimens into perspective with the standard of care treatment with temozolomide and radiotherapy.
Conditions
- Glioblastoma
Interventions
Olaptesed pegolDrug
Olaptesed pegol continuous i.v. administration
RadiotherapyRadiation
Radiotherapy in weeks 1-6; cumulative dose of 60 Gy in 2 Gy fractions
BevacizumabDrug
Bevacizumab every 2 weeks i.v. infusion
PembrolizumabDrug
Pembrolizumab every 3 weeks i.v. for 26 weeks
Temozolomide (TMZ)Drug
oral treatment according to current SPC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety - Number of patients with treatment-related adverse events as assessed by CTCAETime frame: through study completion, an average of 3 years
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Klinik und Poliklinik für Neurologie Schwerpunkt Klinische Neuroonkologie
Bonn, Germany
Klinik für Neurologie
Essen, Germany
Klinik für Strahlentherapie und Radioonkologie
Leipzig, Germany
Klinik für Strahlentherapie und Radioonkologie
Mannheim, Germany
Klinik für Neurologie mit Institut für Translationale Neurologie
Münster, Germany
Abteilung Neurologie mit interdisziplinärem Schwerpunkt Neuroonkologie
Tübingen, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.